Emergent BioSolutions secures $62.4M contract modification from ASPR for botulism antitoxin BAT

Emergent BioSolutions Inc.

Modification and option exercise valued at $62.4 million under existing 10-year ASPR contract (75A50119C00075).
BAT is used to treat symptomatic botulism from exposure to botulinum neurotoxin serotypes A through G.
Supply supports U.S. government stockpile for military and civilian biodefense preparedness.
Paul Williams, SVP, noted the award reinforces Emergent's role in public health countermeasures.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.